News and analysis on disease research and diagnostics.
Test volumes, revenues per test and costs per test improved during the quarter, the company said.
The offering is for 470,000 shares priced at-the-market which the firm will use for infectious disease test supplies and assay development.
The agency said all tests for the virus must pass through its EUA process, but noted a test could be authorized under a single EUA for use in multiple labs.
The organization is looking to fund new tests for rapid detection, stratification, and monitoring of patients.
Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.
